H. Lundbeck A/S HLBBF
Set alert
At close · Oct 30
- YTD
- +3.50%
- 1 year
- -2.74%
- Open
- 7.10
- Prev close
- 7.10
- Mkt cap
- 7.04B
- Vol
- 100
- Avg vol
- 56
- EPS
- 0.61
- P/E
- 11.64
More statistics
- Low
- 7.10
- High
- 7.10
- Earnings
- Aug 19, 2026
News
2 months ago seekingalpha.com
H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript
H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript
4 months ago seekingalpha.com
H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript
H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript
7 months ago seekingalpha.com
H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript
H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript
8 months ago seekingalpha.com
H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript
H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript
11 months ago wsj.com
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
11 months ago seekingalpha.com
H. Lundbeck A/S (HLBBF) Q3 2025 Earnings Call Transcript
H. Lundbeck A/S (OTCPK:HLBBF) Q3 2025 Earnings Call November 12, 2025 7:00 AM EST Company Participants Charl van Zyl - President & CEO Thomas Gibbs - Executive VP & Head of Lundbeck in United States…
1 year ago prnewswire.com
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a…